公开(公告)号：US20100247579A1

公开(公告)日：2010-09-30

申请号：US12599541

申请日：2008-05-08

申请人： Hiroshi Shiku ,  Shinichi Kageyama ,  Shigehisa Kitano ,  Mitsuko Ideno ,  Keisuke Tomita ,  Tatsuji Enoki ,  Kazutoh Takesako ,  Ikunoshin Kato

发明人： Hiroshi Shiku ,  Shinichi Kageyama ,  Shigehisa Kitano ,  Mitsuko Ideno ,  Keisuke Tomita ,  Tatsuji Enoki ,  Kazutoh Takesako ,  Ikunoshin Kato

IPC分类号： A61K39/00 ,  A61K35/12 ,  C12N5/00 ,  A61P35/04

CPC分类号： A61K35/14 ,  A61K39/0011 ,  A61K45/06 ,  C12N5/0636 ,  C12N2501/2302 ,  A61K2300/00

摘要： The present invention relates to a method for treatment of cancer, which comprises the following steps (A) and (B): (A) applying a treatment which induces the reduction in lymphocytes to a patient; and (B), subsequent to step (A), administering lymphocytes to the patient promptly. The present invention also relates to a cancer therapeutic agent and a cancer treatment kit for use in the method. When the method is used as an immunoreconstructive therapy, the decrease in immunologic competence which may be caused by the reduction in lymphocytes can be avoided and, therefore, the risk of the occurrence of an infectious disease can be decreased.

摘要翻译： 本发明涉及一种治疗癌症的方法，其包括以下步骤（A）和（B）：（A）应用诱导淋巴细胞减少至患者的治疗方法; 和（B），在步骤（A）之后，迅速给予患者淋巴细胞。 本发明还涉及用于该方法的癌症治疗剂和癌症治疗试剂盒。 当该方法用作免疫构建性治疗时，可以避免可能由淋巴细胞减少引起的免疫能力的降低，因此可以降低感染性疾病发生的风险。

公开(公告)号：US20110318839A1

公开(公告)日：2011-12-29

申请号：US13254602

申请日：2010-03-05

申请人： Hiroshi Shiku ,  Hiroaki Ikeda ,  Koichi Iwamura ,  Junichi Mineno ,  Ikunoshin Kato

发明人： Hiroshi Shiku ,  Hiroaki Ikeda ,  Koichi Iwamura ,  Junichi Mineno ,  Ikunoshin Kato

IPC分类号： C12N5/0783

CPC分类号： A61K35/17 ,  A61K2035/124 ,  A61K2039/5158 ,  C12N5/0636 ,  C12N15/113 ,  C12N2310/14 ,  C12N2501/48 ,  C12N2501/599 ,  C12N2310/531

摘要： Disclosed is a method for enhancing the function of a T cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (PD-L1) and/or programmed death-1 ligand 2 (PD-L2) in the T cell. Also disclosed is a function-enhanced T cell which is produced by the function enhancement method. Further disclosed is a therapeutic agent comprising the function-enhanced T cell. The T cell can enhance an immune response to cancer, and is useful in an immunotherapy effective for cancer and the treatment or prevention of infectious diseases and autoimmune diseases.

摘要翻译： 公开了一种增强T细胞功能的方法，其特征在于抑制T细胞中程序性死亡-1配体1（PD-L1）和/或程序性死亡-1配体2（PD-L2）的表达 。 还公开了通过功能增强方法产生的功能增强T细胞。 还公开了包含功能增强T细胞的治疗剂。 T细胞可以增强对癌症的免疫应答，并且可用于对癌症有效的免疫治疗和治疗或预防感染性疾病和自身免疫性疾病。

公开(公告)号：US20110250230A1

公开(公告)日：2011-10-13

申请号：US13062999

申请日：2009-09-11

申请人： Hiroshi Shiku ,  Hiroaki Ikeda ,  Jun Mitsui ,  Yuki Takenaka ,  Junichi Mineno ,  Ikunoshin Kato

发明人： Hiroshi Shiku ,  Hiroaki Ikeda ,  Jun Mitsui ,  Yuki Takenaka ,  Junichi Mineno ,  Ikunoshin Kato

IPC分类号： A61K39/00 ,  C12N15/63 ,  A61P35/00 ,  C12N5/10

CPC分类号： A61K39/0005 ,  A61K35/12 ,  A61K38/00 ,  A61K38/191 ,  A61K39/0011 ,  A61K2039/5152 ,  A61K2039/5156 ,  C07K14/70575 ,  C07K2319/30 ,  C12N2799/022 ,  C12N2799/027

摘要： Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject.

摘要翻译： 公开了能够表达外源GITRL或外源性GITRL衍生物的细胞; 电池的制造方法; 包含该细胞作为活性成分的治疗或预防剂; 在制造治疗或预防剂中使用细胞; 一种方法，包括将细胞施用于受试者的步骤; 携带编码GITRL或GITRL衍生物的基因的病毒载体; 包含病毒载体作为活性成分的治疗或预防剂; 病毒载体在制备治疗或预防药物中的应用; 以及包括将病毒载体施用于受试者的步骤的方法。

公开(公告)号：US09181525B2

公开(公告)日：2015-11-10

申请号：US13254602

申请日：2010-03-05

申请人： Hiroshi Shiku ,  Hiroaki Ikeda ,  Koichi Iwamura ,  Junichi Mineno ,  Ikunoshin Kato

发明人： Hiroshi Shiku ,  Hiroaki Ikeda ,  Koichi Iwamura ,  Junichi Mineno ,  Ikunoshin Kato

IPC分类号： C12N15/00 ,  C12N15/11 ,  C12N5/0783 ,  A61K35/17 ,  C12N15/113 ,  A61K35/12 ,  A61K39/00

CPC分类号： A61K35/17 ,  A61K2035/124 ,  A61K2039/5158 ,  C12N5/0636 ,  C12N15/113 ,  C12N2310/14 ,  C12N2501/48 ,  C12N2501/599 ,  C12N2310/531

摘要： Disclosed is a method for enhancing the function of a T cell, which is characterized by inhibiting the expression of programmed death-1 ligand 1 (PD-L1) and/or programmed death-1 ligand 2 (PD-L2) in the T cell. Also disclosed is a function-enhanced T cell which is produced by the function enhancement method. Further disclosed is a therapeutic agent comprising the function-enhanced T cell. The T cell can enhance an immune response to cancer, and is useful in an immunotherapy effective for cancer and the treatment or prevention of infectious diseases and autoimmune diseases.

摘要翻译： 公开了一种增强T细胞功能的方法，其特征在于抑制T细胞中程序性死亡-1配体1（PD-L1）和/或程序性死亡-1配体2（PD-L2）的表达 。 还公开了通过功能增强方法产生的功能增强T细胞。 还公开了包含功能增强T细胞的治疗剂。 T细胞可以增强对癌症的免疫应答，并且可用于对癌症有效的免疫治疗和治疗或预防感染性疾病和自身免疫性疾病。

公开(公告)号：US09051391B2

公开(公告)日：2015-06-09

申请号：US12664133

申请日：2008-06-10

申请人： Junichi Mineno ,  Sachiko Okamoto ,  Risa Sumioka ,  Masanari Kitagawa ,  Hiroshi Shiku ,  Ikunoshin Kato

发明人： Junichi Mineno ,  Sachiko Okamoto ,  Risa Sumioka ,  Masanari Kitagawa ,  Hiroshi Shiku ,  Ikunoshin Kato

IPC分类号： C12P21/06 ,  C12N5/00 ,  C12N15/63 ,  C07K14/725

CPC分类号： C07K14/7051 ,  C12N15/85 ,  C12N2800/40 ,  C12N2840/102

摘要： Disclosed is a cell which can express a non-natural oligomeric protein, which has, introduced therein, a gene encoding an exogenous polypeptide corresponding to at least one endogenous polypeptide constituting a natural oligomeric protein, and in which the expression of the endogenous polypeptide is inhibited.

摘要翻译： 公开了可以表达非天然寡聚蛋白质的细胞，其中引入了编码对应于构成天然寡聚蛋白质的至少一种内源多肽的外源多肽的基因，并且其中内源多肽的表达被抑制 。

公开(公告)号：US08586023B2

公开(公告)日：2013-11-19

申请号：US13062999

申请日：2009-09-11

申请人： Hiroshi Shiku ,  Hiroaki Ikeda ,  Jun Mitsui ,  Yuki Takenaka ,  Junichi Mineno ,  Ikunoshin Kato

发明人： Hiroshi Shiku ,  Hiroaki Ikeda ,  Jun Mitsui ,  Yuki Takenaka ,  Junichi Mineno ,  Ikunoshin Kato

IPC分类号： A61K48/00

CPC分类号： A61K39/0005 ,  A61K35/12 ,  A61K38/00 ,  A61K38/191 ,  A61K39/0011 ,  A61K2039/5152 ,  A61K2039/5156 ,  C07K14/70575 ,  C07K2319/30 ,  C12N2799/022 ,  C12N2799/027

摘要： Disclosed are: a cell capable of expressing an exogenous GITRL or an exogenous GITRL derivative; a method for producing the cell; a therapeutic or prophylactic agent comprising the cell as an active ingredient; use of the cell in the manufacture of a therapeutic or prophylactic agent; a method comprising a step of administering the cell to a subject; a viral vector carrying a gene encoding a GITRL or a GITRL derivative; a therapeutic or prophylactic agent comprising the viral vector as an active ingredient; use of the viral vector in the manufacture of a therapeutic or prophylactic agent; and a method comprising a step of administering the viral vector to a subject.

公开(公告)号：US20100273213A1

公开(公告)日：2010-10-28

申请号：US12664133

申请日：2008-06-06

申请人： Junichi Mineno ,  Sachiko Okamoto ,  Risa Sumioka ,  Masanari Kitagawa ,  Hiroshi Shiku ,  Ikunoshin Kato

发明人： Junichi Mineno ,  Sachiko Okamoto ,  Risa Sumioka ,  Masanari Kitagawa ,  Hiroshi Shiku ,  Ikunoshin Kato

IPC分类号： C12P21/06 ,  C12N5/00 ,  C12N15/63

CPC分类号： C07K14/7051 ,  C12N15/85 ,  C12N2800/40 ,  C12N2840/102

摘要： Disclosed is a cell which can express a non-natural oligomeric protein, which has, introduced therein, a gene encoding an exogenous polypeptide corresponding to at least one endogenous polypeptide constituting a natural oligomeric protein, and in which the expression of the endogenous polypeptide is inhibited.

摘要翻译： 公开了可以表达非天然寡聚蛋白质的细胞，其中引入了编码对应于构成天然寡聚蛋白质的至少一种内源多肽的外源多肽的基因，并且其中内源多肽的表达被抑制 。

公开(公告)号：US20140322344A1

公开(公告)日：2014-10-30

申请号：US14241321

申请日：2012-08-30

申请人： Hiroshi Shiku ,  Naozumi Harada ,  Daisuke Muraoka ,  Kazunari Akiyoshi

发明人： Hiroshi Shiku ,  Naozumi Harada ,  Daisuke Muraoka ,  Kazunari Akiyoshi

IPC分类号： A61K39/385 ,  A61K39/39

CPC分类号： A61K39/385 ,  A61K39/0011 ,  A61K45/06 ,  A61K47/61 ,  A61K2039/55511 ,  A61K2039/55561 ,  A61K2039/6087 ,  C07K14/4748 ,  C07K2319/00 ,  C07K2319/40 ,  C12N15/117 ,  C12N2310/17 ,  A61K2300/00

摘要： A vaccine preparation for treating cancer includes a complex of a hydrophobized polysaccharide and at least one synthetic long peptide derived from a tumor-specific antigenic protein and/or a pathogen-derived antigenic protein. The at least one synthetic long peptide contains at least one CD8+ cytotoxic T-cell recognition epitope and at least one CD4+ helper T-cell recognition epitope. The complex is simultaneously administered to the patient with at least one immunopotentiating agent.

摘要翻译： 用于治疗癌症的疫苗制剂包括疏水化多糖和衍生自肿瘤特异性抗原蛋白和/或病原体衍生抗原蛋白的至少一种合成长肽的复合物。 所述至少一种合成长肽含有至少一种CD8 +细胞毒性T细胞识别表位和至少一种CD4 +辅助T细胞识别表位。 使用至少一种免疫增强剂将复合物同时施用于患者。

公开(公告)号：US07414032B2

公开(公告)日：2008-08-19

申请号：US10746747

申请日：2003-12-23

申请人： Hiroshi Shiku

发明人： Hiroshi Shiku

IPC分类号： A01K43/04 ,  A61K31/70

CPC分类号： A61K39/0011 ,  A61K2039/53 ,  A61K2300/00

摘要： The present invention relates to a DNA vaccine for developing tumor-specific immunity. Specifically, the invention relates to a DNA vaccine comprising antigens recognized by CD4+ helper T cells and CD8+ cytotoxic T cells, respectively. Preferably, the antigen recognized by CD4+ helper T cells is a molecule identified by the SEREX method and that recognized by CD8+ cytotoxic T cells is a tumor-specific antigen, tumor-associated antigen or cell-associated antigen. Furthermore, so that the antigens recognized by CD4+ helper T cells and CD8+ CTL are expressed and presented on the same cell, the expression vectors preferably are immobilized on the same gold particle and administered into the cell by gene gun; however, this invention is not restricted thereto. The vaccine can also be used as a pharmaceutical agent.

摘要翻译： 本发明涉及用于发展肿瘤特异性免疫的DNA疫苗。 具体地，本发明涉及分别包含被CD4 +辅助T细胞和CD8 +细胞毒性T细胞识别的抗原的DNA疫苗。 优选地，由CD4 +辅助T细胞识别的抗原是通过SEREX方法鉴定的分子，并且被CD8 +细胞毒性T细胞识别的是肿瘤特异性抗原，肿瘤 相关抗原或细胞相关抗原。 此外，使得由CD4 +辅助T细胞和CD8 + CTL识别的抗原被表达并存在于相同的细胞上，表达载体优选固定在相同的金 颗粒并通过基因枪施用于细胞; 然而，本发明不限于此。 疫苗也可以用作药剂。

公开(公告)号：US20060182721A1

公开(公告)日：2006-08-17

申请号：US10565273

申请日：2004-07-22

申请人： Naoyuki Katayama ,  Koshi Oishi ,  Hiroshi Shiku

发明人： Naoyuki Katayama ,  Koshi Oishi ,  Hiroshi Shiku

IPC分类号： A61K35/12 ,  C12N5/08

CPC分类号： C12N5/0639 ,  A61K2035/124 ,  C12N2501/15 ,  C12N2501/22 ,  C12N2501/42

摘要： This invention provides a method for preparing Langerhans cells from CD14-positive cells, which are human peripheral blood mononuclear cells. This method comprises culturing human peripheral blood mononuclear cells in the presence of Notch ligand, GM-CSF, and TGF-β.

摘要翻译： 本发明提供了作为人外周血单核细胞的CD14阳性细胞制备朗格汉斯细胞的方法。 该方法包括在Notch配体，GM-CSF和TGF-β的存在下培养人外周血单核细胞。